Want to see TARS full AI Analyst Report?
TARS Stock Chart & Stats
$58.66
$0.08(0.14%)
At close: 4:00 PM EDT
$58.66
$0.08(0.14%)
Day’s Range― - ―
52-Week Range$48.20 - $85.25
Previous CloseN/A
Volume446.51K
Average Volume (3M)1.22M
Market Cap
$3.19B
Enterprise Value$2.37K
Total Cash (Recent Filing)$449.69M
Total Debt (Recent Filing)$88.66M
Price to Earnings (P/E)―
Beta0.12
Next Earnings
Nov 10, 2026EPS Estimate
-1.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.09
Shares Outstanding43,882,996
10 Day Avg. Volume1,253,369
30 Day Avg. Volume1,215,310
Financial Highlights & Ratios
PEG Ratio1.07
Price to Book (P/B)9.96
Price to Sales (P/S)7.58
P/FCF Ratio-153.35
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$95.71Price Target Upside63.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-2.18
Revenue Forecast (FY)$714.25M
Bulls Say, Bears Say
Bulls Say
XDEMVY Growth And AdoptionRapid prescription growth, broad patient experience, and increasing prescriber engagement support XDEMVY’s durability. The expanding treated base and nearly $1B in cumulative sales strengthen commercial infrastructure and provide a larger recurring revenue foundation.
High Margins And Improving Cash GenerationThe product’s exceptionally high gross margin creates meaningful operating leverage as sales scale. Positive operating and free cash flow also improve internal funding capacity, although continued execution is needed to demonstrate that the cash conversion is sustainable.
Expansion Into Retinal TherapeuticsThe Alkeus transaction broadens Tarsus beyond Demodex blepharitis into a late-stage retinal program addressing a disease with no FDA-approved treatment. Successful development could diversify future revenue and create a larger ophthalmology platform.
Bears Say
Persistent Operating LossesDespite strong revenue growth and gross margins, Tarsus has not yet converted its commercial scale into consistent profitability. Continued selling, general, administrative, and research spending could delay earnings inflection and reduce the durability of reported cash generation.
Acquisition Funding And Dilution BurdenThe Alkeus investment commits substantial cash and equity before clinical value is realized. Milestones, royalties, and stock consideration may pressure liquidity, increase dilution, and constrain flexibility if development costs or commercialization needs exceed current plans.
Long And Competitive Retina Development PathThe retinal pipeline offers no near-term revenue replacement because its pivotal readout is years away. A competing Phase 3 program may also affect enrollment, regulatory positioning, payer access, and eventual commercial share, increasing execution risk.
Tarsus Pharmaceuticals News
TARS FAQ
What was Tarsus Pharmaceuticals, Inc.’s price range in the past 12 months?
Tarsus Pharmaceuticals, Inc. lowest stock price was $48.20 and its highest was $85.25 in the past 12 months.
What is Tarsus Pharmaceuticals, Inc.’s market cap?
Tarsus Pharmaceuticals, Inc.’s market cap is $3.19B.
When is Tarsus Pharmaceuticals, Inc.’s upcoming earnings report date?
Tarsus Pharmaceuticals, Inc.’s upcoming earnings report date is Nov 10, 2026 which is in 79 days.
How were Tarsus Pharmaceuticals, Inc.’s earnings last quarter?
Tarsus Pharmaceuticals, Inc. released its earnings results on Aug 06, 2026. The company reported -$0.43 earnings per share for the quarter, missing the consensus estimate of -$0.192 by -$0.238.
Is Tarsus Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Tarsus Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Tarsus Pharmaceuticals, Inc. pay dividends?
Tarsus Pharmaceuticals, Inc. does not currently pay dividends.
What is Tarsus Pharmaceuticals, Inc.’s EPS estimate?
Tarsus Pharmaceuticals, Inc.’s EPS estimate is -1.59.
How many shares outstanding does Tarsus Pharmaceuticals, Inc. have?
Tarsus Pharmaceuticals, Inc. has 43,882,996 shares outstanding.
What happened to Tarsus Pharmaceuticals, Inc.’s price movement after its last earnings report?
Tarsus Pharmaceuticals, Inc. reported an EPS of -$0.43 in its last earnings report, missing expectations of -$0.192. Following the earnings report the stock price went up 6.592%.
Which hedge fund is a major shareholder of Tarsus Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in TARS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tarsus Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$95.71 (63.17% Upside)
$95.71 (63.17% Upside)
Blogger Sentiment
Bullish
TARS Sentiment 80%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 604.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.2%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
38.21%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
23.46%
Trailing 12-Months
Company Description
Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
TARS Company Deck
TARS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong commercial execution and robust growth driven by XDEMVY (record quarterly sales, improved full-year guidance, high margins, strong physician and patient engagement) while also announcing a transformative but costly acquisition of Alkeus to enter retina. The ALK-001 program brings promising long-term upside (solid clinical data, favorable tolerability, Phase III underway) but also increases near-term R&D and transaction-related cash commitments, extends the timeline to value realization (topline 2H 2029), and introduces competitive and payer uncertainties. Overall, operational momentum and financial flexibility support growth and strategic investment, but the company will incur higher expenses and execution risk ahead of the eventual retina readouts.View all TARS earnings summariesTARS Stock 12 Month Forecast
Average Price Target
$95.71
▲(63.17% Upside)
Technical Analysis
Denali Therapeutics
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Disc Medicine
―
Recursion Pharmaceuticals
―
Ownership Overview
3.20% Insiders
21.12% Mutual Funds
49.68% Other Institutional Investors
13.45% Public Companies and
Individual Investors